Rockefeller Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Rockefeller Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.59K	Sell	820 -1,791	-69%	-$5.01K	﹤0.01%	4368
2026 Q1	$7.15K	Buy	2,611 +1,891	+263%	+$5.99K	﹤0.01%	4128
2025 Q4	$2.66K	Buy	+720	New	+$2.33K	﹤0.01%	4247
2023 Q1	–	Sell	-200	Closed	-$1K	–	2558
2022 Q4	$1K	Hold	200	–	–	﹤0.01%	3674
2022 Q3	$1K	Hold	200	–	–	﹤0.01%	3704
2022 Q2	$1K	Hold	200	–	–	﹤0.01%	3940
2022 Q1	$0	Hold	200	–	–	﹤0.01%	3917
2021 Q4	$1K	Hold	200	–	–	﹤0.01%	3630
2021 Q3	$2K	Hold	200	–	–	﹤0.01%	3425
2021 Q2	$4K	Sell	200 -500	-71%	-$12K	﹤0.01%	3080
2021 Q1	$19K	Buy	700 +500	+250%	+$14.8K	﹤0.01%	2299
2020 Q4	$5K	Hold	200	–	–	﹤0.01%	2424
2020 Q3	$7K	Hold	200	–	–	﹤0.01%	2109
2020 Q2	$10K	Hold	200	–	–	﹤0.01%	1893
2020 Q1	$6K	Hold	200	–	–	﹤0.01%	1888
2019 Q4	$12K	Buy	+200	New	+$8.99K	﹤0.01%	1555

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.56% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Rockefeller Capital Management's ESPR Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Esperion Therapeutics (ESPR) stake by 69% in Q2 2026, selling an estimated $5.01K and leaving 820 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #4368.

Rockefeller Capital Management first reported a position in ESPR in Q4 2019 and has held it in 16 quarters since. The position peaked at $19K in Q1 2021. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Rockefeller Capital Management held 820 shares of Esperion Therapeutics worth $2.59K as of Q2 2026.
Rockefeller Capital Management sold 1,791 Esperion Therapeutics shares in Q2 2026, an estimated $5.01K.
Esperion Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4368 holding.
Rockefeller Capital Management first reported a position in Esperion Therapeutics in Q4 2019 and has held it in 16 quarters since.
Rockefeller Capital Management's Esperion Therapeutics position peaked at $19K in Q1 2021.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.